Current Edition

Australasia

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence supports activity of PBT434 to prevent α-synuclein accumulation …

Continue Reading →